Gildas AGODOKPESSI

Prof. Gildas AGODOKPESSI

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
AHAntoine Vikkey Hinson
Antoine Vikkey Hinson
VLVirgil K. Lokossou
Virgil K. Lokossou
Vivi SchlünssenVivi Schlünssen
Vivi Schlünssen
GAGildas AGODOKPESSI
Gildas AGODOKPESSI
TSTorben Sigsgaard
Torben Sigsgaard
BFBenjamin Fayomi
Benjamin Fayomi
The textile industry sector occupies a prominent place in the economy of Benin. It exposes workers to several occupational risks, including exposure to cotton dust. To assess the effect of exposure to cotton dust on the health of workers, this study was initiated and conducted in a Beninese cotton industry company. The objective of the study was to evaluate the respiratory disorders among the textile workers exposed to cotton dust and the cross-sectional study involved 656 subjects exposed to cotton dust and 113 non-exposed subjects. The methods used are mainly based on a survey using a questionnaire of organic dust designed by the International Commission of Occupational Health (ICOH); and on the measures of lung function parameters (FEV1 and FVC). The main results of the different analyzes revealed that subjects exposed to cotton dust have more respiratory symptoms than unexposed subjects (36.9% vs. 21.2%). The prevalence of chronic cough, expectorations, dyspnoea, asthma and chronic bronchitis are 16.8%, 9.8%, 17.3%, 2.6%, and 5.9% respectively among the exposed versus 2.6%, 0.8%, 16.8%, 0% and 0.8% among the unexposed subjects. The prevalence of byssinosis is 44.01%.The prevalence of symptoms is dependent on the sector of activity and the age of the subject. These results should encourage medical interventions and technical prevention especially since the textile industry occupies an important place in the Benin’s economy.

1 December 2015 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
SASerge Ade
Serge Ade
ATArnaud Trebucq
Arnaud Trebucq
Anthony HarriesAnthony Harries
Anthony Harries
GAGabriel Ade
Gabriel Ade
GAGildas AGODOKPESSI
Gildas AGODOKPESSI
SASévérin Anagonou
Sévérin Anagonou
In the “Centre National Hospitalier de Pneumo-Phtisiologie” of Cotonou, Benin, little is known about the characteristics of patients who have not attended their scheduled appointment, the results of tracing and the possible benefits on improving treatment outcomes. This study aimed to determine the contribution of tracing activities for those who missed scheduled appointments towards a successful treatment outcome. A retrospective cohort study was carried out among all smear-positive pulmonary tuberculosis patients treated between January and September 2013. Data on demographic and diagnostic characteristics and treatment outcomes were accessed from tuberculosis registers and treatment cards. Information on those who missed their scheduled appointments was collected from the tracing tuberculosis register. A univariate analysis was performed to explore factors associated with missing a scheduled appointment. Of 457 patients (410 new smear-positive and 47 retreatment tuberculosis), 37 (8 %) missed one or more of their appointments with a total of 44 episodes of missed appointments. The 3.5th (32 %) and 5th (43 %) month appointments were the ones most likely to be missed. Being male was associated with a higher risk of missing appointments (RR = 4.2; 95 % CI = 1.5–11.8, p = 0.004) while having HIV infection was associated with a lower risk (RR = 0.3, 95 % CI = 0.1–0.9, p = 0.03). Principal reasons for missed appointments were travelling outside Cotonou (34 %) and feeling better (21 %). In 24 (55 %) of these 44 episodes of missed appointments, contact was made with the patient who returned to the programme. These follow-up activities increased the treatment success by 4 %. In Cotonou, Benin, less than 10 % of tuberculosis patients miss at least one of their scheduled appointments. Tracing activities increase the treatment success rate by 4 % and current on-going practices in the Programme need to be endorsed and encouraged.

13 April 2015 in Journal of Pharmaceutical Policy and Practice
Verified
Journal Article
Open access
PDF file
GAGildas AGODOKPESSI
Gildas AGODOKPESSI
NANadia Aït-Khaled
Nadia Aït-Khaled
MGMartin Gninafon
Martin Gninafon
LTLeon Tawo
Leon Tawo
WBWilfried Bekou
Wilfried Bekou
CCChen-Yuan Chiang
Chen-Yuan Chiang
Benin established a revolving drug fund (RDF) for essential asthma medicines in 2008. We evaluated the operation of the RDF and assessed whether there was interruption of supply of asthma medicine from 2008 to 2013. We reviewed the process in establishing the RDF. We assessed cost and sale price of asthma medicines, expenditure of the RDF in procuring asthma medicines and other tools, revenue generated by sales of medicines to patients, and balance of capital as of 31 January 2013. We investigated whether there was interruption of supply of essential asthma medicines from 2008–2013. The total amount of grants initially injected into the RDF was 24,101€. As of 31 January 2013, the capital of the RDF, including the deposit in the RDF bank account (8,114€) and the value of inhalers in stock (12,172€), was equivalent to 20,586€, slightly less than the initial capital (24,101€). The decrease of capital was mainly because a number of inhalers were expired or provided free-of-charge (6,091€) and because part of the fund was used to procure other elements required for the management of asthma (4,338€). Thanks to a RDF, Benin maintained an uninterrupted supply of essential asthma medicines in asthma pilot sites from 2008–2013. The Benin experience demonstrated that in countries where universal health coverage was not yet in place, establishment of a RDF may help maintain an uninterrupted supply of essential medicines.

1 November 2012 in Medecine Et Maladies Infectieuses
Verified
Journal Article
Closed access
GAGildas AGODOKPESSI
Gildas AGODOKPESSI
GAG. Ade
G. Ade
SAS. Ade
S. Ade
AWA.P. Wachinou
A.P. Wachinou
DAD. Affolabi
D. Affolabi
MGM. Gninafon
M. Gninafon

1 February 2019 in Revue des Maladies Respiratoires
Verified
Journal Article
Closed access
GAGildas AGODOKPESSI
Gildas AGODOKPESSI
GSG. Sagbo
G. Sagbo
CBC. Bigot
C. Bigot
THT. Hountohotegbe
T. Hountohotegbe
SDS. Dossou-Yovo
S. Dossou-Yovo
ABA. Bigot
A. Bigot

1 November 2013 in Revue des Maladies Respiratoires
Verified
Journal Article
Closed access
GAGildas AGODOKPESSI
Gildas AGODOKPESSI
GAG. Ade
G. Ade
BNB.H. Mbatchou Ngahane
B.H. Mbatchou Ngahane
SAS. Ade
S. Ade
AWA.P. Wachinou
A.P. Wachinou
MGM. Gninafon
M. Gninafon